“LL-37” can refer to an endogenous human defense peptide, a synthetic assay reagent or an engineered biological delivery system. Results from one of those interventions cannot be transferred automatically to another.
What the record shows
- Endogenous expression is not evidence for exogenous administration.
- An engineered organism expressing LL-37 is not equivalent to isolated synthetic LL-37.
- FDA reports insufficient human safety information and flags immunogenicity, reproductive and tissue-specific tumor concerns.
The identity and evidence boundary
A paper about an LL-37-expressing microorganism tests the complete engineered intervention, including its delivery system. It should not be cited as if participants received a vial of isolated LL-37.
What belongs in the material record
For material characterization, sequence confirmation, purity, mass, aggregation and endotoxin or bioburden controls answer different questions. None supplies a human efficacy conclusion.
Editorial rule
Use the exact intervention name, model, population and endpoint from the cited record. Do not convert an association, mechanism, animal result, approved finished-drug record or analytical test into a claim about an unrelated catalog lot.
Sources & editorial method
The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.
3 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Source-checked on 2026-08-28. Null findings and study limitations are retained. This is not independent peer review, medical advice, a customer case, or validation of a catalog lot.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- LL-37 ocular-surface expression and antimicrobial activityGordon YJ, et al. Current Eye Research. 2005. PMID 16020269.
- LL-37 analog activity, cytotoxicity and serum inhibitionIn-vitro context; PMID 15980359.
- Certain Bulk Drug Substances That May Present Significant Safety RisksU.S. FDA. Current compounding safety-information page.
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
